产品
编 号：F601572
分子式：C50H68Cl6N8O10S2
分子量：1217.97
分子式：C50H68Cl6N8O10S2
分子量：1217.97
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1234365-97-9
产品详情
生物活性：
Tenapanor (AZD1722) hydrochloride is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor hydrochloride reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor hydrochloride has the potential for the research of hyperphosphatemia.
体内研究：
Tenapanor hydrochloride (0.15, 0.5 mg/kg; p.o.) reduces passive paracellular phosphate absorption in rats.Tenapanor hydrochloride (0.15 mg/kg; p.o.; twice-daily for 11 consecutive days) increases the reduction in urinary phosphorus excretion in rats.Animal Model:Rats (intestinal loop model)
Dosage:0.15, 0.5 mg/kg
Administration:P.o.
Result:Reduced passive paracellular phosphate absorption by reduced urinary phosphate and sodium excretion after the high-phosphate meal and increased sodium and phosphate delivery to the cecum.
Animal Model:8 weeks, 250 g male Sprague–Dawley rats
Dosage:0.15 mg/kg in combination with sevelamer (0%, 0.75%, 1.5%, and 3% (wt/wt))
Administration:Oral gavage; twice-daily for 11 consecutive days
Result:Significantly augmented the reduction in urinary phosphorus excretion.
Tenapanor (AZD1722) hydrochloride is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor hydrochloride reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor hydrochloride has the potential for the research of hyperphosphatemia.
体内研究：
Tenapanor hydrochloride (0.15, 0.5 mg/kg; p.o.) reduces passive paracellular phosphate absorption in rats.Tenapanor hydrochloride (0.15 mg/kg; p.o.; twice-daily for 11 consecutive days) increases the reduction in urinary phosphorus excretion in rats.Animal Model:Rats (intestinal loop model)
Dosage:0.15, 0.5 mg/kg
Administration:P.o.
Result:Reduced passive paracellular phosphate absorption by reduced urinary phosphate and sodium excretion after the high-phosphate meal and increased sodium and phosphate delivery to the cecum.
Animal Model:8 weeks, 250 g male Sprague–Dawley rats
Dosage:0.15 mg/kg in combination with sevelamer (0%, 0.75%, 1.5%, and 3% (wt/wt))
Administration:Oral gavage; twice-daily for 11 consecutive days
Result:Significantly augmented the reduction in urinary phosphorus excretion.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备